Arkema
Arkema is a French specialty chemicals and advanced materials company (Euronext: AKE) with EUR 9.5B in 2024 revenues, producing products including Paladin®EC, a dimethyl disulfide (DMDS)-based soil fumigant positioned as a methyl bromide alternative for pre-plant treatment in fruit and vegetable crops.
Arkema
Arkema is a French specialty chemicals and advanced materials company (Euronext: AKE) with EUR 9.5B in 2024 revenues, producing products including Paladin®EC, a dimethyl disulfide (DMDS)-based soil fumigant positioned as a methyl bromide alternative for pre-plant treatment in fruit and vegetable crops.
Executive Summary
Arkema is a well-established, publicly traded specialty chemicals leader with a credible EUR 9.5B revenue base, a highly regarded CEO, and a genuine structural tailwind in the Paladin EC soil fumigant product via the ongoing methyl bromide phase-out. The market claims are grounded — the global agricultural fumigants market sits at USD 1.2–1.8B (2024–2025 consensus) and is growing at 4–5.5% CAGR — but Paladin EC is a niche product within Arkema's much larger portfolio, and the "MB alternative" differentiation is not unique. The single biggest issue here, full stop, is PFAS litigation: Arkema is named in over a dozen active U.S. lawsuits across municipalities, firefighters, and utilities, faces a criminal environmental complaint in France, and has operating permits under legal challenge — with total exposure unquantified but potentially material given 3M's $10.3B settlement precedent. Any investor considering Arkema must stress-test the PFAS contingent liability against the company's EUR 1.5B EBITDA base before forming a view on valuation.
Run your own diligence
Upload a pitch deck or paste any company URL to get a full AI-powered due diligence report in under 2 minutes.
Get started free →Free plan available · No credit card required